Alumis Inc (ALMS)

$17.92 +1.69 (10.41%)
Market Cap 934.84M
Revenue (ttm) 0.00
Net Income (ttm) -294.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 9,351,958
Avg Vol 2,397,350
Day's Range N/A - N/A
Shares Out 104.39M
Stochastic %K 58%
Beta -2.09
Analysts Strong Sell
Price Target $19.86

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to ad...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
10xby3
10xby3 Jan. 7 at 10:48 PM
$ALMS so quiet right before JP morgan healthcare conference next week in San Fran where HQ is - hmmmmm 💰💰💰
0 · Reply
NIQUEDSI
NIQUEDSI Jan. 7 at 10:39 PM
$GME $APLD $SOFI $ALMS
0 · Reply
Donniechen12345
Donniechen12345 Jan. 7 at 9:11 PM
$ALMS 700 k shares to go :)$$
1 · Reply
10xby3
10xby3 Jan. 7 at 9:07 PM
$ALMS open $19-20 and will keep flying
0 · Reply
underpaidpumper
underpaidpumper Jan. 7 at 8:57 PM
$ALMS not holding 18 not a great sign into close
1 · Reply
CrumbEater
CrumbEater Jan. 7 at 8:36 PM
$ALMS $$$$
0 · Reply
Donniechen12345
Donniechen12345 Jan. 7 at 8:27 PM
$ALMS 1.9 mil left :)$$
1 · Reply
hope8361
hope8361 Jan. 7 at 8:17 PM
$ALMS According to AI best case scenario for stock price for offering is around $17, but a more realistic would be at $16. Any feedback??
1 · Reply
Donniechen12345
Donniechen12345 Jan. 7 at 8:03 PM
$ALMS 2.4 million shares left to pump $$$$$
0 · Reply
topstockalerts
topstockalerts Jan. 7 at 7:56 PM
$ALMS heating up…
0 · Reply
Latest News on ALMS
Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise

Jan 7, 2026, 11:22 AM EST - 6 hours ago

Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise

Alumis Announces Proposed Public Offering of Common Stock

Jan 6, 2026, 4:12 PM EST - 1 day ago

Alumis Announces Proposed Public Offering of Common Stock

Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars

Jan 6, 2026, 10:47 AM EST - 1 day ago

Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars

Alumis skin disease drug meets main goal of two late-stage trials

Jan 6, 2026, 7:07 AM EST - 1 day ago

Alumis skin disease drug meets main goal of two late-stage trials

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Jan 6, 2026, 7:00 AM EST - 1 day ago

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Jan 5, 2026, 5:00 PM EST - 2 days ago

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 13, 2025, 4:15 PM EST - 7 weeks ago

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis to Participate in Upcoming November Investor Conferences

Nov 4, 2025, 8:00 AM EST - 2 months ago

Alumis to Participate in Upcoming November Investor Conferences

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Sep 17, 2025, 4:53 AM EDT - 4 months ago

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Alumis to Participate in Upcoming September Investor Conferences

Aug 29, 2025, 7:00 AM EDT - 4 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 5 months ago

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Jul 24, 2025, 7:30 AM EDT - 5 months ago

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Jul 14, 2025, 4:05 PM EDT - 6 months ago

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025, 4:15 PM EDT - 7 months ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 29, 2025, 7:55 AM EDT - 7 months ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 8 months ago

Alumis Completes Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 14, 2025, 4:05 PM EDT - 8 months ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 8 months ago

Alumis Stockholders Approve Merger with ACELYRIN

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 9 months ago

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Apr 16, 2025, 5:31 PM EDT - 9 months ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

Apr 14, 2025, 10:02 AM EDT - 9 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO AMRN CCO ECX HZO NUTX

Top 3 Health Care Stocks That May Crash In Q2

Apr 7, 2025, 11:23 AM EDT - 9 months ago

Top 3 Health Care Stocks That May Crash In Q2

CMRX DERM

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Apr 4, 2025, 4:34 PM EDT - 9 months ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 25, 2025, 2:30 AM EDT - 10 months ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 19, 2025, 4:05 PM EDT - 10 months ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 10 months ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 8, 2025, 9:00 AM EST - 10 months ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:01 AM EST - 11 months ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Mar 4, 2025, 9:00 AM EST - 11 months ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 28, 2025, 9:08 AM EST - 11 months ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 27, 2025, 4:15 PM EST - 11 months ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 4:45 PM EST - 11 months ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

Feb 7, 2025, 3:22 PM EST - 11 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Feb 6, 2025, 4:15 PM EST - 11 months ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 1 year ago

Alumis Strengthens Leadership Team with Key Appointments

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Nov 13, 2024, 4:05 PM EST - 1 year ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Oct 17, 2024, 2:32 PM EDT - 1 year ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

BMY

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Oct 4, 2024, 2:00 AM EDT - 1 year ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 27, 2024, 9:00 AM EDT - 1 year ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Sep 16, 2024, 4:32 PM EDT - 1 year ago

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Jul 24, 2024, 3:18 PM EDT - 1 year ago

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

Jul 1, 2024, 11:51 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

AGH INHI LB LINE TBN TWFG WBTN

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Jun 28, 2024, 1:36 PM EDT - 1 year ago

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:58 PM EDT - 1 year ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Jun 28, 2024, 12:43 AM EDT - 1 year ago

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Alumis Announces Pricing of Initial Public Offering

Jun 27, 2024, 11:57 PM EDT - 1 year ago

Alumis Announces Pricing of Initial Public Offering

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Jun 24, 2024, 8:27 AM EDT - 1 year ago

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

10xby3
10xby3 Jan. 7 at 10:48 PM
$ALMS so quiet right before JP morgan healthcare conference next week in San Fran where HQ is - hmmmmm 💰💰💰
0 · Reply
NIQUEDSI
NIQUEDSI Jan. 7 at 10:39 PM
$GME $APLD $SOFI $ALMS
0 · Reply
Donniechen12345
Donniechen12345 Jan. 7 at 9:11 PM
$ALMS 700 k shares to go :)$$
1 · Reply
10xby3
10xby3 Jan. 7 at 9:07 PM
$ALMS open $19-20 and will keep flying
0 · Reply
underpaidpumper
underpaidpumper Jan. 7 at 8:57 PM
$ALMS not holding 18 not a great sign into close
1 · Reply
CrumbEater
CrumbEater Jan. 7 at 8:36 PM
$ALMS $$$$
0 · Reply
Donniechen12345
Donniechen12345 Jan. 7 at 8:27 PM
$ALMS 1.9 mil left :)$$
1 · Reply
hope8361
hope8361 Jan. 7 at 8:17 PM
$ALMS According to AI best case scenario for stock price for offering is around $17, but a more realistic would be at $16. Any feedback??
1 · Reply
Donniechen12345
Donniechen12345 Jan. 7 at 8:03 PM
$ALMS 2.4 million shares left to pump $$$$$
0 · Reply
topstockalerts
topstockalerts Jan. 7 at 7:56 PM
$ALMS heating up…
0 · Reply
GreenorGo
GreenorGo Jan. 7 at 7:51 PM
$ALMS Extremely bullish pattern on the weekly chart 🚀🚀🚀
0 · Reply
Donniechen12345
Donniechen12345 Jan. 7 at 7:46 PM
$ALMS 2.8 million shares to go $19!!!!!! lets go !!!!$$$$
0 · Reply
Donniechen12345
Donniechen12345 Jan. 7 at 7:18 PM
$ALMS 3.2 million left !!!!!! lets go!!!!’nn $18….$19 !!!
0 · Reply
Swihart_Art
Swihart_Art Jan. 7 at 7:17 PM
$ALMS this breaks 18 it's going to 20...
0 · Reply
10xby3
10xby3 Jan. 7 at 7:02 PM
$ALMS $20 lets go
0 · Reply
AKnewMann
AKnewMann Jan. 7 at 6:59 PM
$ALMS shorts are going to get impatient and move on... HODL for gold
0 · Reply
Donniechen12345
Donniechen12345 Jan. 7 at 6:58 PM
$ALMS 3.3 mil shares left to pump by the algos
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Jan. 7 at 6:53 PM
$ALMS Buy a bottle of Nizoral at CVS, move on...
1 · Reply
murphylaw
murphylaw Jan. 7 at 6:38 PM
$ALMS even if this drops, this is the best in class product in Psoriasis in tablet form. Your stock is only as good as the product you invest in. Watch it grow all next week during JPM 2026 conference. You'll get more short term and long term gain with this product. You will regret not investing in this company in 3 to 6 months.
0 · Reply
ZacksResearch
ZacksResearch Jan. 7 at 6:37 PM
$ALMS explodes higher — this is what breakout biotech wins look like 🚀 Alumis shares surged 95% after envudeucitinib met all endpoints in two phase III plaque psoriasis studies, delivering strong skin clearance results. That’s a rare, clean win across late-stage trials — and the market is reacting fast. See the full study results and what drove the surge 👉 https://www.zacks.com/stock/news/2813597/alms-surges-as-envudeucitinib-meets-goals-in-plaque-psoriasis-studies?cid=sm-stocktwits-2-2813597-teaser-27846&ADID=SYND_STOCKTWITS_TWEET_2_2813597_TEASER_27846
0 · Reply
wfinvestor
wfinvestor Jan. 7 at 6:24 PM
$ALMS just come down to 14 please.
0 · Reply
Burn0505
Burn0505 Jan. 7 at 5:49 PM
$ALMS take profits. Always..already run 100%. Goodluck! Buying around $10.
0 · Reply